DOCSLIB.ORG

Laws, Rules, and Regulations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laws, Rules, and Regulations LAWS, RULES, AND REGULATIONS August 2020 Asa Hutchinson, Governor John Clay Kirtley, Pharm.D. Executive Director Arkansas Department of Health Arkansas State Board of Pharmacy 322 South Main Street, Suite 600 Little Rock, AR 72201 Phone: 501.682.0190 Fax: 501.682.0195 [email protected] www.pharmacyboard.arkansas.gov 10/8/2020 Arkansas State Board of Pharmacy Members Lenora Newsome, P.D. President, Smackover Rebecca Mitchell, Pharm.D. Vice President/Secretary, Greenbrier Deborah Mack, P.D. Member, Bentonville Lynn Crouse, Pharm.D. Member, Lake Village Brian Jolly, Pharm.D. Member, Beebe Carol Rader, RN Public Member, Fort Smith Amy Fore, MHSA, FACMPE, FACHE Public Member, Fort Smith 10/8/2020 Board of Pharmacy Law Book - Acts Table of Contents Pharmacy Practice Act A 17-92-101 Definitions……………………………………………………… 1-4 17-92-102 Exemptions…………………………………………………….. 4-5 17-92-103 Pharmacy laws unaffected……………………………………... 5 17-92-104 Privilege tax unaffected……………………………………….. 5 17-92-105 Prohibited acts – Penalties……………………………………... 6 17-92-106 Injunctions……………………………………………………… 6 17-92-107 Prosecutions – Disposition of fines……………………………. 6 17-92-108 Fees…………………………………………………………….. 6-10 17-92-109 Prescriptions for optometrists………………………………….. 10 17-92-110 Prescriptive authority of advance practice nurses……………… 10 17-92-111 Construction of Acts 1997, No. 1204………………………….. 10 17-92-112 Prescriptions for physician assistants…………………………. 10 17-92-201 Members – Qualifications……………………………………… 11 17-92-202 Members – Oath……………………………………………… 11 17-92-203 Members – Compensation…………………………………….. 11 17-92-204 Organization and proceedings…………………………………. 12 17-92-205 Rules and regulations – Enforcement………………………….. 12-13 17-92-206 Issuance of bulletins – Annual Reports………………………... 14 17-92-207 Maintenance of office………………………………………….. 14 17-92-208 Employees……………………………………………………… 14 17-92-209 Medications Administration Advisory Committee…………….. 15 17-92-301 License Required………………………………………………. 15 17-92-302 Unlicensed practice – Penalty…………………………………. 15-16 17-92-303 Unlawful use of professional title – Penalty…………………… 16 17-92-304 Board administration – Support services………………………. 16 17-92-305 Application – Qualification of applicants……………………… 16-17 17-92-306 Examinations…………………………………………………… 17 17-92-307 Internship required……………………………………………... 17 17-92-308 Reciprocity……………………………………………………... 17-18 17-92-309 Registration and certificate…………………………………….. 18 17-92-310 Failure to renew………………………………………………... 18-19 17-92-311 Revocation, suspension, or non-renewal – Grounds…………… 19-20 17-92-312 Revocation and fine – Adulteration of drugs…………………... 20 17-92-313 Revocation – Procedure………………………………………... 20 17-92-314 Revocation – Appeals………………………………………….. 20 17-92-315 Alternative penalties…………………………………………… 20-21 17-92-316 Credential required for professional pharmacy service………... 21-22 17-92-317 Criminal Background Checks………………………………….. 22-24 17-92-401 Applicability to out-of-state operations………………………... 24-25 17-92-402 Licensed pharmacist required………………………………….. 25 17-92-403 Licensed pharmacist required – Exceptions…………………… 25-27 17-92-404 Pharmacy permit required……………………………………… 27 i 17-92-405 Pharmacy permit – Application………………………………... 27-28 17-92-407 Revocation – Grounds………………………………………….. 28 17-92-408 Revocation – Procedure………………………………………... 28 17-92-409 Pharmacy library required……………………………………… 28-29 17-92-410 Records of poison sales………………………………………… 29 17-92-411 Prescription contents and labels………………………………... 29 17-92-412 Nursing home consultant permit……………………………….. 29-30 17-92-501 Penalty………………………………………………………….. 30 17-92-502 Rules and regulations…………………………………………... 30 17-92-503 Generic substitutions…………………………………………… 30-31 17-92-505 Labeling………………………………………………………… 31 17-92-506 Price Lists………………………………………………………. 31 17-92-601 Short title……………………………………………………….. 32 17-92-602 Definitions……………………………………………………… 32 17-92-603 Advisory Committee for Hospital Pharmacies………………… 32 17-92-604 Regulatory authority…………………………………………… 32-33 17-92-605 Hospital pharmacy license – Services permitted………………. 33 17-92-606 Hospital pharmaceutical permit………………………………... 34 17-92-607 Unlawful for hospital to hold licensed pharmacy permit – 34 Exemptions…………………………………………………….. 17-92-701 Definitions……………………………………………………… 34 17-92-702 Administration………………………………………………….. 34-35 17-92-703 Functions……………………………………………………….. 35 17-92-704 Board review…………………………………………………… 35 17-92-705 Notification of procedures, rights, and responsibilities – Failure 35 to comply……………………………………………………….. 17-92-706 Funding………………………………………………………… 35-36 17-92-707 Liability………………………………………………………… 36 17-92-801 Powers and duties of Arkansas State Board of Pharmacy……... 36 17-92-901 Definitions……………………………………………………… 36-37 17-92-902 License required………………………………………………... 37-38 17-92-903 Exemption from license and permit requirements……………... 38-39 17-92-904 Supply order required………………………………………….. 39 17-92-905 Labeling………………………………………………………… 39 17-92-906 Regulations……………………………………………………... 39-40 17-92-907 Manufacture, shipment, or sale of medical gases……………… 40 17-92-908 Revocation or suspension of license…………………………… 40-41 17-92-909 Advisory committee to the board………………………………. 41 17-92-1001 Title…………………………………………………………….. 41 17-92-1002 Purpose…………………………………………………………. 41 17-92-1003 Definitions……………………………………………………… 41-43 17-92-1004 Requirements for Internet sales………………………………… 43 17-92-1005 Requirements for Internet sites………………………………… 43-44 17-92-1006 Disclaimers or limitations of liabilities………………………… 44 17-92-1007 Enforcement……………………………………………………. 44 ii Miscellaneous Statutes Related to B Pharmacy 17-1-103 Registration, certification, and licensing for criminal 1 offenders………………………………………………………... 17-80-102 Subpoena power of boards – Enforcement…………………….. 1-2 17-80-103 Immunity of board members…………………………………… 2 17-80-104 Continuing education requirements……………………………. 2-3 iii Uniform Controlled Substances Act C 5-64-101 Definitions……………………………………………………… 1-6 5-64-201 Director’s duties………………………………………………... 6-7 5-64-202 Nomenclature…………………………………………………... 7 5-64-203 Criteria for Schedule I………………………………………….. 7 5-64-205 Criteria for Schedule II…………………………………………. 7 5-64-207 Criteria for Schedule III………………………………………... 7 5-64-209 Criteria for Schedule IV………………………………………... 8 5-64-211 Criteria for Schedule V………………………………………… 8 5-64-213 Schedule VI established………………………………………... 8 5-64-214 Criteria for Schedule VI………………………………………... 8 5-64-215 Substances in Schedule VI……………………………………... 8-9 5-64-216 Schedule revisions……………………………………………… 9 5-64-307 Order forms…………………………………………………….. 9 5-64-308 Written prescriptions…………………………………………… 9 5-64-1005 Exemptions……………………………………………………... 9-10 5-64-1006 Suspicious order reports………………………………………... 10-11 5-64-1101 Possession – Penalty…………………………………………… 11 5-64-1102 Possession with intent to manufacture – Unlawful 11-12 distribution……………………………………………………… 5-64-1003 Retail sales limit………………………………………………... 12-14 iv Insurance Policies – Prescription D Drug Benefits 23-79-149 Prescription drug benefits……………………………………… 1 23-79-601 Definitions……………………………………………………… 2 23-79-602 Diabetes self-management training – Licensed providers – 2-3 Prescription by physician………………………………………. 23-79-603 Requirements…………………………………………………… 3 23-79-604 Exclusions……………………………………………………… 3 23-79-605 Regulations……………………………………………………... 3 23-79-606 Applicability – Delivery within state…………………………... 3-4 23-79-607 Applicability – Exceptions……………………………………... 4 v Food, Drug, and Cosmetic Act E 20-56-201 Title…………………………………………………………….. 1 20-56-202 Definitions……………………………………………………… 1-3 20-56-203 Applicability……………………………………………………. 3 20-56-204 Notice of minor violations……………………………………… 3 20-56-205 Penalties – Exceptions………………………………………….. 3-4 20-56-206 Duty of prosecuting attorney…………………………………… 4 20-56-207 Injunction authorized…………………………………………… 4-5 20-56-208 Adulterated food……………………………………………….. 5-6 20-56-209 Misbranded food………………………………………………... 6-7 20-56-210 Adulterated drug or device……………………………………... 7-8 20-56-211 Misbranded drug or device……………………………………... 8-10 20-56-212 Adulterated cosmetic…………………………………………… 10-11 20-56-213 Misbranded cosmetic…………………………………………… 11 20-56-214 False or misleading advertisement……………………………... 11-12 20-56-215 Prohibited acts………………………………………………….. 12 20-56-216 Adulterated, misbranded, or abandoned food, drug, device, or 13-14 cosmetic – Procedures………………………………………….. 20-56-217 Contamination with microorganisms…………………………... 14 20-56-218 Poisonous or deleterious substance – Regulation for use………. 14-15 20-56-219 State Board of Health – Authority to regulate………………….. 15 20-56-220 State Board of Health – Inspection……………………………... 15-16 20-56-221 State Board of Health – Publication and dissemination of 16 information……………………………………………………... 20-56-222 State Board of Health – Enforcement of subchapter…………… 16 20-56-223 State Board of Health – Enforcement of federal law…………... 16 vi Controlled Substances and Legend F Drugs 20-64-501 Applicability……………………………………………………. 1 20-64-502 Construction……………………………………………………. 1 20-64-503 Definitions……………………………………………………… 1-3 20-64-504 Sales – Permit required…………………………………………. 3 20-64-505 Wholesale distributor – Permit required……………………….. 3 20-64-506 Wholesale distributors – Shipment to certain licensed 3 professionals……………………………………………………. 20-64-507 Regulations……………………………………………………... 4 20-64-508 Revocation or suspension of licenses…………………………... 4 20-64-509 Penalties………………………………………………………… 4-5 20-64-510 Hearing procedures……………………………………………... 5 20-64-511
Load more

Recommended publications
  • 615 Neuroscience-Cayman-Bertin
    Thomas G. Brock, Ph.D. Introduction to Neuroscience In our first Biology classes, we learned that lipids form the membranes around cells. For many students, interests quickly moved to the intracellular constituents ‘that really matter’, or to how cells or systems work in health and disease. If there was further thought about lipids, it might have been limited to more personal issues, like an expanding waistline. It was easy to forget about lipids in the complexities of, say, Alzheimer’s Disease, where tau protein is hyperphosphorylated by a host of kinases before forming neurofibrillary tangles and amyloid precursor protein is processed by assorted secretases, ultimately aggregating to form neurodegenerating plaques. What possible role could lipids have in all this? After all, lipids just form the membranes around cells. Fortunately, neuroscientists study complex systems. Whether working at the molecular, cellular, or organismal level, the research focus always returns to the intricately interconnected bigger picture. Perhaps surprisingly, lipids keep emerging as part of the bigger picture. At least, the smaller lipids do. Many of the smaller lipids, including the cannabinoids and eicosanoids, act as paracrine hormones, modulating cell functions in a receptor-mediated fashion. In this sense, they are rather like the peptide hormones in their diversity and actions. In the neurosystem, this means that these signaling lipids determine if synapses fire or not, when cells differentiate or die, and whether tissues remain healthy or become inflamed. Returning to the question posed above about lipids in Alzheimer’s, these mediators have roles at many levels in the course of the disease, as presented in an article on page 42 of this catalog.
    [Show full text]
  • Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
    cancers Review Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer Viktoriia Cherkasova, Olga Kovalchuk * and Igor Kovalchuk * Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 7X8, Canada; [email protected] * Correspondence: [email protected] (O.K.); [email protected] (I.K.) Simple Summary: In recent years, multiple preclinical studies have shown that changes in endo- cannabinoid system signaling may have various effects on intestinal inflammation and colorectal cancer. However, not all tumors can respond to cannabinoid therapy in the same manner. Given that colorectal cancer is a heterogeneous disease with different genomic landscapes, experiments with cannabinoids should involve different molecular subtypes, emerging mutations, and various stages of the disease. We hope that this review can help researchers form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases. We believe that selecting a particular experimental model based on the disease’s genetic landscape is a crucial step in the drug discovery, which eventually may tremendously benefit patient’s treatment outcomes and bring us one step closer to individualized medicine. Abstract: Despite the multiple preventive measures and treatment options, colorectal cancer holds a significant place in the world’s disease and mortality rates. The development of novel therapy is in Citation: Cherkasova, V.; Kovalchuk, critical need, and based on recent experimental data, cannabinoids could become excellent candidates. O.; Kovalchuk, I. Cannabinoids and This review covered known experimental studies regarding the effects of cannabinoids on intestinal Endocannabinoid System Changes in inflammation and colorectal cancer. In our opinion, because colorectal cancer is a heterogeneous Intestinal Inflammation and disease with different genomic landscapes, the choice of cannabinoids for tumor prevention and Colorectal Cancer.
    [Show full text]
  • Targeting the Endocannabinoid System to Reduce Nociception
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2011 Targeting the endocannabinoid system to reduce nociception Lamont Booker Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2419 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Targeting the Endocannabinoid System to Reduce Nociception A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By Lamont Booker Bachelor’s of Science, Fayetteville State University 2003 Master’s of Toxicology, North Carolina State University 2005 Director: Dr. Aron H. Lichtman, Professor, Pharmacology & Toxicology Virginia Commonwealth University Richmond, Virginia April 2011 Acknowledgements The author wishes to thank several people. I like to thank my advisor Dr. Aron Lichtman for taking a chance and allowing me to work under his guidance. He has been a great influence not only with project and research direction, but as an excellent example of what a mentor should be (always willing to listen, understanding the needs of each student/technician, and willing to provide a hand when available). Additionally, I like to thank all of my committee members (Drs. Galya Abdrakmanova, Francine Cabral, Sandra Welch, Mike Grotewiel) for your patience and willingness to participate as a member. Our term together has truly been memorable! I owe a special thanks to Sheryol Cox, and Dr.
    [Show full text]
  • 2-Arachidonoylglycerol a Signaling Lipid with Manifold Actions in the Brain
    Progress in Lipid Research 71 (2018) 1–17 Contents lists available at ScienceDirect Progress in Lipid Research journal homepage: www.elsevier.com/locate/plipres Review 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain T ⁎ Marc P. Baggelaara,1, Mauro Maccarroneb,c,2, Mario van der Stelta, ,2 a Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. b Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy c European Centre for Brain Research/IRCCS Santa Lucia Foundation, via del Fosso del Fiorano 65, 00143 Rome, Italy ABSTRACT 2-Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the cannabinoid CB1 receptor. It is involved in a wide array of (patho)physiological functions, such as emotion, cognition, energy balance, pain sensation and neuroinflammation. In this review, we describe the biosynthetic and metabolic pathways of 2-AG and how chemical and genetic perturbation of these pathways has led to insight in the biological role of this signaling lipid. Finally, we discuss the potential therapeutic benefits of modulating 2-AG levels in the brain. 1. Introduction [24–26], locomotor activity [27,28], learning and memory [29,30], epileptogenesis [31], neuroprotection [32], pain sensation [33], mood 2-Arachidonoylglycerol (2-AG) is one of the most extensively stu- [34,35], stress and anxiety [36], addiction [37], and reward [38]. CB1 died monoacylglycerols. It acts as an important signal and as an in- receptor signaling is tightly regulated by biosynthetic and catabolic termediate in lipid metabolism [1,2].
    [Show full text]
  • SYNTHESIS of 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES and THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation
    TKK Dissertations 203 Espoo 2009 SYNTHESIS OF 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES AND THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation Mikko Myllymäki Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry TKK Dissertations 203 Espoo 2009 SYNTHESIS OF 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES AND THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation Mikko Myllymäki Dissertation for the degree of Doctor of Philosophy to be presented with due permission of the Faculty of Chemistry and Materials Sciences for public examination and debate in Auditorium KE2 (Komppa Auditorium) at Helsinki University of Technology (Espoo, Finland) on the 19th of December, 2009, at 12 noon. Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry Teknillinen korkeakoulu Kemian ja materiaalitieteiden tiedekunta Kemian laitos Distribution: Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry P.O. Box 6100 (Kemistintie 1) FI - 02015 TKK FINLAND URL: http://chemistry.tkk.fi/ Tel. +358-9-470 22527 Fax +358-9-470 22538 E-mail: [email protected] © 2009 Mikko Myllymäki ISBN 978-952-248-240-2 ISBN 978-952-248-241-9 (PDF) ISSN 1795-2239 ISSN 1795-4584 (PDF) URL: http://lib.tkk.fi/Diss/2009/isbn9789522482419/ TKK-DISS-2686 Multiprint Oy Espoo 2009 3 AB HELSINKI UNIVERSITY OF TECHNOLOGY ABSTRACT OF DOCTORAL DISSERTATION P.O. BOX 1000, FI-02015 TKK http://www.tkk.fi Author Mikko Juhani Myllymäki Name of the dissertation
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Cannabinoids for the Control of Experimental Multiple Sclerosis Pryce, Gareth
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Queen Mary Research Online Cannabinoids for the control of experimental multiple sclerosis Pryce, Gareth The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author For additional information about this publication click this link. https://qmro.qmul.ac.uk/jspui/handle/123456789/673 Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] 1 Cannabinoids for the control of experimental multiple sclerosis GARETH PRYCE Neuroimmunology Unit, Neuroscience & Trauma Barts and the London School of Medicine and Dentistry Queen Mary University of London UK 2 This thesis is dedicated in memory of my Dad, Glyn Pryce (1927-2010), with love and thanks. 3 ACKNOWLEDGEMENTS I wouldlike to thank DavidBaker andGavin Giovannoni for their supervision and providingme with the opportunity to undertake this thesis. I wouldlike to thank J.Ludovic Croxford, Sam Jackson, Sarah Al-Izki from the lab past and present; Ana Cabranes (RIP) and the Javier Fernadez-Ruiz laboratory in Madrid, Spain; the Vincenzo Di Marzio Laboratory Naples, Italy; the Andy Irving Laboratory, Dundee; the laboratories of Elga De Vries andSandra Amor at the Free University Amsterdam, The Netherlands and the laboratories of Ruth Ross and Roger Pertwee in Aberdeen and Alison Hardcastle University College London for providing me with supportive data and particularly Cristina Visintin and David Selwoodof University College London andCanbex for providingdata from contract Research organizations.
    [Show full text]
  • A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain
    Clinical and Translational Science Institute Centers 1-1-2018 The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain Giulia Donvito Virginia Commonwealth University Sara R. Nass West Virginia University Jenny L. Wilkerson Virginia Commonwealth University Zachary A. Curry Virginia Commonwealth University Lesley D. Schurman Virginia Commonwealth University See next page for additional authors Follow this and additional works at: https://researchrepository.wvu.edu/ctsi Part of the Medicine and Health Sciences Commons Digital Commons Citation Donvito, Giulia; Nass, Sara R.; Wilkerson, Jenny L.; Curry, Zachary A.; Schurman, Lesley D.; Kinsey, Steven G.; and Lichtman, Aron H., "The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain" (2018). Clinical and Translational Science Institute. 717. https://researchrepository.wvu.edu/ctsi/717 This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Authors Giulia Donvito, Sara R. Nass, Jenny L. Wilkerson, Zachary A. Curry, Lesley D. Schurman, Steven G. Kinsey, and Aron H. Lichtman This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/ctsi/717 Neuropsychopharmacology REVIEWS (2018) 43, 52–79 © 2018 American
    [Show full text]
  • 2012 Meeting Program
    30th Annual Meeting of the South Central Chapter of the Society of Toxicology “Advancing Toxicology for 30 Years” November 1-2, 2012 Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 30th Annual Meeting of the South Central Chapter of the Society of Toxicology November 1-2, 2012 Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR “Advancing Toxicology for 30 Years” Thursday, November 1 Juanita’s, 614 President Clinton Ave., Little Rock, AR 6:30 – 9:00 PM Reception - Fajita Feast with cash bar Sponsored by Center for Toxicology & Environmental Health LLC Friday, November 2 Donald W. Reynolds Institute on Aging University of Arkansas for Medical Sciences Little Rock, AR 7:30 – 8:00 AM Continental Breakfast 8:00 – 8:15 AM Welcome & Opening Remarks Dr. Martin Ronis, Chair Local Organizing Committee Dr. Barbara Parsons, President SCC-SOT 8:15 – 9:15 AM Keynote Address – Dr. Russell S. Thomas Senior Investigator and Director of the Institute for Chemical Safety Sciences at The Hamner Institutes for Health Sciences, Research Triangle Park, NC. “Incorporating New Technologies into Toxicity Testing and Risk Assessment: Moving from 21st Century Vision to a Data- Driven Framework” 9:15 – 9:30 AM Jone Corrales, University of Mississippi, “Transcriptome analyses of benzo[a]pyrene exposure in zebrafish embryos and larvae” (Platform Presentation 1) 9:30 – 9:45 AM Syed Z. Imam, US FDA/National Center for Toxicological Research, “Hyperglycemia mitigates Parkinson’s disease: in vitro, animal model and clinical epidemiologic evidence” (Platform Presentation 2) 9:45 – 10:00 AM Sarah J.
    [Show full text]
  • Compartmentalization of Endocannabinoids Into Lipid Rafts In
    British Journal of DOI:10.1111/j.1476-5381.2011.01380.x www.brjpharmacol.org BJP Pharmacology Themed Section: Cannabinoids in Biology and Medicine, Part II Correspondence Neta Rimmerman, Arison Building 302, Department of RESEARCH PAPERbph_1380 2436..2449 Neurobiology, Weizmann Institute of Science, Rehovot, 76100, Israel. E-mail: [email protected] Compartmentalization of ---------------------------------------------------------------- Keywords cannabinoid; endocannabinoid; endocannabinoids into lipid lipid raft; membrane raft; microglia; Caveolin-1; flotillin-1; cannabidiol; CB1 receptor; mass rafts in a microglial cell line spectrometry ---------------------------------------------------------------- devoid of caveolin-1 Received 5 December 2010 Revised Neta Rimmerman1, Heather B Bradshaw2, Ewa Kozela3, Rivka Levy1, 3 March 2011 Ana Juknat3 and Zvi Vogel3 Accepted 10 March 2011 1Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel, 2Psychological and brain sciences, Indiana University, Bloomington, IN, USA, and 3Department of Physiology and Pharmacology, Sakler School of Medicine, the Dr Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Tel Aviv University, Ramat Aviv, Israel BACKGROUND AND PURPOSE N-acyl ethanolamines (NAEs) and 2-arachidonoyl glycerol (2-AG) are endogenous cannabinoids and along with related lipids are synthesized on demand from membrane phospholipids. Here, we have studied the compartmentalization of NAEs and 2-AG into lipid raft fractions isolated from the caveolin-1-lacking microglial cell line BV-2, following vehicle or cannabidiol (CBD) treatment. Results were compared with those from the caveolin-1-positive F-11 cell line. EXPERIMENTAL APPROACH BV-2 cells were incubated with CBD or vehicle. Cells were fractionated using a detergent-free continuous OptiPrep density gradient. Lipids in fractions were quantified using HPLC/MS/MS.
    [Show full text]
  • Cannabinoids in Biology and Medicine
    Joint Research Conference of the Institute for Advanced Studies and the Israel Science Foundation Cannabinoids in Biology and Medicine brain Jerusalem, October 31 - November 4, 2010 cardiovascular skin muscle liver gastrointestinal Joints urinary bladder bone reproductive Director: Itai Bab Co-directors: Ester Fride, Confirmed Invited Speakers Esther Shohami, Zvi Vogel Heather Bradshaw, Bloomington, Indiana Mauro Maccarrone, Teramo, Italy Benjamin Cravatt, La Jolla, California Ken Mackie, Bloomington, Indiana Dale Deutch, Stony Brook, New York Raphael Mechoulam, Jerusalem, Israel Vincenzo Di Marzo, Pozzuoli, Italy Pál Pacher, Bethesda, Maryland Javier Fernández-Ruiz, Madrid, Spain Linda Parker, Guelph, Ontario Cecilia Hillard, Milwaukee, Wisconsin Daniela Parolaro, Busto Arsizio, Italy Andrea Hohmann, Athens, Georgia Roger Pertwee, Aberdeen, UK Allyn Howlett, Durham, North Carolina Daniele Piomelli, Irvine, California George Kunos, Bethesda, Maryland Neta Rimmerman, Rehovot, Israel Aron Lichtman, Richmond, Virginia Ethan Russo, Vashon, Washington Sophie Lotersztajn, Créteil, France Yosef Sarne, Tel Aviv, Israel Beat Lutz, Mainz, Germany Mone Zaidi, New York, New York Mary Lynch, Halifax, Nova Scotia Andreas Zimmer, Bonn, Germany Additional sponsors: Contact: www.as.huji.ac.il//isf/cannabinoids/ Joint Research Conference of the Institute for Advanced Studies and the Israel Science Foundation WORKSHOP PROGRAM CANNABINOIDS IN BIOLOGY AND MEDICINE OCTOBER 31 – NOVEMBER 4, 2010 Director: Itai Bab, The Hebrew University of Jerusalem Codirectors:
    [Show full text]
  • CAY10499, a Novel Monoglyceride Lipase Inhibitor Evidenced by an Expeditious Mglassay Giulio G
    DOI: 10.1002/cbic.200800428 CAY10499, a Novel Monoglyceride Lipase Inhibitor Evidenced by an Expeditious MGLAssay Giulio G. Muccioli,* Geoffray Labar, and Didier M. Lambert*[a] ACHTUNGRE Monoglyceride lipase (MGL) plays a major role in the metabolism labeled substrate, 4-nitrophenylacetate. The IC50 valuesthat were of the lipid transmitter 2-arachidonoylglycerol (2-AG). This endo- obtained for known inhibitorsof MGL using4-nitrophenylacetate cannabinoid isknown to mediate a large number of physiologi- were similar to those reported by using the radiolabeled form of cal processes, and its regulation is thought to be of great thera- an endogenous substrate, 2-oleoylglycerol. In a first small-scale peutic potential. However, the number of available monoglycer- screening, we identified CAY10499 as a novel monoglyceride ide lipase inhibitors is limited, mostly due to the lack of rapid lipase inhibitor. Thus, we report here the characterization of this and accurate pharmacological assays for the enzyme. We have submicromolar inhibitor, which acts on MGL through an unprece- developed a 96-well-format assay for MGL using a nonradio- dented mechanism for inhibitors of this enzyme. Introduction 2-Arachidonoyglycerol (2-AG) is a lipid messenger that primari- (MAFP),[6] the less-potent carbamate derivative URB602,[14] and ly actsby binding to the cannabinoid G protein-coupled recep- the thiuram derivative disulfiram.[15] This disappointing situa- torsCB 1 and CB2. Unlike classical neurotransmitters, 2-AG is not tion might have arisen from the quite expensive and painstak- stored in vesicles prior to its release; instead, it is produced on ing assay procedures that are most commonly used nowadays demand from membrane lipid precursors.[1,2] After itsaction, 2- to screen for and to characterize MGL inhibitors.
    [Show full text]